Minoxidil
Also known as: Rogaine, Regaine
Vasodilator | Hair Growth Stimulation
Overview
Minoxidil is an FDA-approved vasodilator originally developed in the 1970s as an oral antihypertensive medication. Its hair growth properties were discovered as a side effect, and topical formulations (2% and 5%) were subsequently approved for the treatment of androgenetic alopecia. It remains one of only two FDA-approved treatments for pattern hair loss and is available over the counter in most countries. In recent years, off-label oral minoxidil at low doses (0.625-5mg) has gained significant traction among dermatologists and the biohacker community as a more convenient and potentially more effective alternative to topical application, particularly for individuals who find the topical formulation inconvenient or who experience scalp irritation.
Key benefits
- FDA-approved for androgenetic alopecia with decades of clinical evidence
- Stimulates new hair growth and increases hair follicle size independent of androgen pathways
- Available over the counter as a topical treatment without a prescription
- Effective in both men and women for pattern hair loss
- Low-dose oral formulation offers a convenient once-daily alternative to twice-daily topical application
- Synergistic with finasteride and dutasteride for a multi-mechanism approach to hair loss
- Extends the anagen (growth) phase and shortens the telogen (resting) phase of the hair cycle
Mechanism of action
Minoxidil is a potassium channel opener that acts on ATP-sensitive potassium channels in vascular smooth muscle cells, causing vasodilation. When applied topically or taken orally, it is converted to its active metabolite minoxidil sulfate by the enzyme sulfotransferase (SULT1A1) in hair follicle outer root sheath cells. The sulfated form opens potassium channels in dermal papilla cells and vascular smooth muscle surrounding hair follicles, increasing local blood flow and nutrient delivery. Beyond vasodilation, minoxidil upregulates vascular endothelial growth factor (VEGF) expression, extends the anagen (growth) phase of the hair cycle, increases follicle size, and stimulates the transition of resting follicles from telogen into anagen. It also has anti-fibrotic properties that may benefit the perifollicular environment. Notably, minoxidil's hair growth effects are androgen-independent, making it effective regardless of DHT levels and complementary to 5-alpha reductase inhibitors like finasteride.
Molecular data
- Type
- Synthetic pyrimidine derivative (6-amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine)
- Half-life
- ~4 hours (oral); topical effects persist significantly longer due to local tissue retention
Indications
What the research community uses this compound for, with self-reported effectiveness.
Hair Loss
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 1mL of 5% solution or half a capful of 5% foam | Twice daily (morning and evening) | — |
| — | 1mL of 2% solution or 5% foam once daily | Once to twice daily depending on formulation | — |
| — | 1mL of 5% solution or foam | Once daily (some users step down from twice daily after stabilization) | — |
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 0.625-1.25mg | Once daily | — |
| — | 2.5mg | Once daily | — |
| — | 5mg | Once daily | — |
| — | 0.625-1.25mg | Once daily | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Scalp irritation, dryness, or flaking (topical, especially solution formulations containing propylene glycol)
- Initial shedding phase during the first 1-3 months of treatment
- Hypertrichosis (unwanted facial and body hair growth, more common with oral administration)
- Fluid retention and mild peripheral edema (oral)
- Mild dizziness or lightheadedness upon standing (oral, due to vasodilation)
Rare side effects
- Pericardial effusion (fluid around the heart, primarily associated with higher oral doses used for hypertension)
- Reflex tachycardia (increased heart rate as a compensatory response to vasodilation)
- Significant hypotension (low blood pressure), especially when combined with other antihypertensives
- Allergic contact dermatitis (topical, typically a reaction to propylene glycol rather than minoxidil itself)
- Changes in hair color or texture
Contraindications
- Known hypersensitivity to minoxidil or any component of the formulation
- Pheochromocytoma (minoxidil may stimulate catecholamine release)
- Significant cardiovascular disease, including history of pericardial effusion or congestive heart failure
- Concurrent use of potent antihypertensive medications without physician supervision (risk of additive hypotension)
- Pregnancy and breastfeeding (Category C; oral minoxidil has shown evidence of fetal harm in animal studies)
References
Primary literature and clinical-trial data informing this entry.